The global anti-microbial/anti-fungal tests market is expected to reach USD 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~USD 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.
| Attributes | Key Insights |
|---|---|
| Anti-microbial/Anti-fungal Tests Market Value 2021 | USD 2.4 Billion |
| Estimated Market Size 2022 | USD 2.5 Billion |
| Projected Market Value 2032 | USD 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Market Share of Top 5 Countries | 55.0% |
Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.
Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.
As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~USD 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.
Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.
As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.
The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.
Favorable Government Initiatives and Awareness Programs to Fuel the Growth
Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.
Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.
The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.
Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.
Growing Preference for Diagnostic Tests to Boost the Sales
The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.
Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China
China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.
Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.
It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.
Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection
Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.
This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.
Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond
Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.
Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.
Nearly 2 out of 5 Sales are Contributed by Hospitals
As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.
With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
| Attribute | Details |
|---|---|
| Estimated Market Size 2022 | USD 2.5 Billion |
| Projected Market Value 2032 | USD 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa |
| Key Market Segments Covered | Tests, Infection, End User, and Region |
| Key Companies Profiled | Abbott Laboratories; bioMérieux SA; Bio-Rad Laboratories Inc; Bruker Corporation; Danaher Corporation; Erba Mannheim; F. Hoffmann-La Roche AG; Luminex Corporation; Meridian Bioscience Inc; Norgen Biotek Corp; Omega Diagnostics Group Plc; Qiagen N.V; Quidel Corporation; Thermo Fisher Scientific Inc |
Table 01: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 02: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Infection
Table 03: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 04: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
Table 05: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 06: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 07: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection
Table 08: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 09: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 10: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection
Table 12: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 13: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 14: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 15: Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Infection
Table 16: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 17: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 18: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 19: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection
Table 20: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 21: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 22: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 23: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Infection
Table 24: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 25: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 26: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 27: Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Infection
Table 28: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Table 29: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country
Table 30: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Test
Table 31: Middle East & Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Infection
Table 32: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by End User
Figure 01: Global Market Value (US$ Million) Analysis, 2012 to 2021
Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032
Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032
Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Test
Figure 05: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Test
Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Test
Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Infection
Figure 08: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Infection
Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Infection
Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by End User
Figure 11: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by End User
Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by End User
Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Region
Figure 14: Global Market Y-o-Y Growth (%) Analysis 2022 to 2032, by Region
Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Region
Figure 16: North America Market Value (US$ Million) Analysis, 2012 to 2021
Figure 17: North America Market Value (US$ Million) Forecast, 2022 to 2032
Figure 18: North America Market Value Share, by Test (2022 E)
Figure 19: North America Market Value Share, by Infection (2022 E)
Figure 20: North America Market Value Share, by End User (2022 E)
Figure 21: North America Market Value Share, by Country (2022 E)
Figure 22: North America Market Attractiveness Analysis by Test, 2022 to 2032
Figure 23: North America Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 24: North America Market Attractiveness Analysis by End User, 2022 to 2032
Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 26: USA Market Value Proportion Analysis, 2021
Figure 27: Global Vs. USA Growth Comparison, 2021 to 2032
Figure 28: USA Market Share Analysis (%) by Test, 2021 to 2032
Figure 29: USA Market Share Analysis (%) by Infection, 2021 to 2032
Figure 30: USA Market Share Analysis (%) by End User, 2021 to 2032
Figure 31: Canada Market Value Proportion Analysis, 2021
Figure 32: Global Vs. Canada. Growth Comparison, 2021 to 2032
Figure 33: Canada Market Share Analysis (%) by Test, 2021 to 2032
Figure 34: Canada Market Share Analysis (%) by Infection, 2021 to 2032
Figure 35: Canada Market Share Analysis (%) by End User, 2021 to 2032
Figure 36: Latin America Market Value (US$ Million) Analysis, 2012 to 2021
Figure 37: Latin America Market Value (US$ Million) Forecast, 2022 to 2032
Figure 38: Latin America Market Value Share, by Test (2022 E)
Figure 39: Latin America Market Value Share, by Infection (2022 E)
Figure 40: Latin America Market Value Share, by End User (2022 E)
Figure 41: Latin America Market Value Share, by Country (2022 E)
Figure 42: Latin America Market Attractiveness Analysis by Test, 2022 to 2032
Figure 43: Latin America Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 44: Latin America Market Attractiveness Analysis by End User, 2022 to 2032
Figure 45: Latin America Market Attractiveness Analysis by Country, 2022 to 2032
Figure 46: Mexico Market Value Proportion Analysis, 2021
Figure 47: Global Vs Mexico Growth Comparison, 2021 to 2032
Figure 48: Mexico Market Share Analysis (%) by Test, 2021 to 2032
Figure 49: Mexico Market Share Analysis (%) by Infection, 2021 to 2032
Figure 50: Mexico Market Share Analysis (%) by End User, 2021 to 2032
Figure 51: Brazil Market Value Proportion Analysis, 2021
Figure 52: Global Vs. Brazil. Growth Comparison, 2021 to 2032
Figure 53: Brazil Market Share Analysis (%) by Test, 2021 to 2032
Figure 54: Brazil Market Share Analysis (%) by Infection, 2021 to 2032
Figure 55: Brazil Market Share Analysis (%) by End User, 2021 to 2032
Figure 56: Argentina Market Value Proportion Analysis, 2021
Figure 57: Global Vs Argentina Growth Comparison, 2021 to 2032
Figure 58: Argentina Market Share Analysis (%) by Test, 2021 to 2032
Figure 59: Argentina Market Share Analysis (%) by Infection, 2021 to 2032
Figure 60: Argentina Market Share Analysis (%) by End User, 2021 to 2032
Figure 61: Europe Market Value (US$ Million) Analysis, 2012 to 2021
Figure 62: Europe Market Value (US$ Million) Forecast, 2022 to 2032
Figure 63: Europe Market Value Share, by Test (2022 E)
Figure 64: Europe Market Value Share, by Infection (2022 E)
Figure 65: Europe Market Value Share, by End User (2022 E)
Figure 66: Europe Market Value Share, by Country (2022 E)
Figure 67: Europe Market Attractiveness Analysis by Test, 2022 to 2032
Figure 68: Europe Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 69: Europe Market Attractiveness Analysis by End User, 2022 to 2032
Figure 70: Europe Market Attractiveness Analysis by Country, 2022 to 2032
Figure 71: UK Market Value Proportion Analysis, 2021
Figure 72: Global Vs. UK Growth Comparison, 2021 to 2032
Figure 73: UK Market Share Analysis (%) by Test, 2021 to 2032
Figure 74: UK Market Share Analysis (%) by Infection, 2021 to 2032
Figure 75: UK Market Share Analysis (%) by End User, 2021 to 2032
Figure 76: Germany Market Value Proportion Analysis, 2021
Figure 77: Global Vs. Germany Growth Comparison, 2021 to 2032
Figure 78: Germany Market Share Analysis (%) by Test, 2021 to 2032
Figure 79: Germany Market Share Analysis (%) by Infection, 2021 to 2032
Figure 80: Germany Market Share Analysis (%) by End User, 2021 to 2032
Figure 81: Italy Market Value Proportion Analysis, 2021
Figure 82: Global Vs. Italy Growth Comparison, 2021 to 2032
Figure 83: Italy Market Share Analysis (%) by Test, 2021 to 2032
Figure 84: Italy Market Share Analysis (%) by Infection, 2021 to 2032
Figure 85: Italy Market Share Analysis (%) by End User, 2021 to 2032
Figure 86: France Market Value Proportion Analysis, 2021
Figure 87: Global Vs France Growth Comparison, 2021 to 2032
Figure 88: France Market Share Analysis (%) by Test, 2021 to 2032
Figure 89: France Market Share Analysis (%) by Infection, 2021 to 2032
Figure 90: France Market Share Analysis (%) by End User, 2021 to 2032
Figure 91: Spain Market Value Proportion Analysis, 2021
Figure 92: Global Vs Spain Growth Comparison, 2021 to 2032
Figure 93: Spain Market Share Analysis (%) by Test, 2021 to 2032
Figure 94: Spain Market Share Analysis (%) by Infection, 2021 to 2032
Figure 95: Spain Market Share Analysis (%) by End User, 2021 to 2032
Figure 96: Russia Market Value Proportion Analysis, 2021
Figure 97: Global Vs Russia Growth Comparison, 2021 to 2032
Figure 98: Russia Market Share Analysis (%) by Test, 2021 to 2032
Figure 99: Russia Market Share Analysis (%) by Infection, 2021 to 2032
Figure 100: Russia Market Share Analysis (%) by End User, 2021 to 2032
Figure 101: BENELUX Market Value Proportion Analysis, 2021
Figure 102: Global Vs BENELUX Growth Comparison, 2021 to 2032
Figure 103: BENELUX Market Share Analysis (%) by Test, 2021 to 2032
Figure 104: BENELUX Market Share Analysis (%) by Infection, 2021 to 2032
Figure 105: BENELUX Market Share Analysis (%) by End User, 2021 to 2032
Figure 106: East Asia Market Value (US$ Million) Analysis, 2012 to 2021
Figure 107: East Asia Market Value (US$ Million) Forecast, 2022 to 2032
Figure 108: East Asia Market Value Share, by Test (2022 E)
Figure 109: East Asia Market Value Share, by Infection (2022 E)
Figure 110: East Asia Market Value Share, by End User (2022 E)
Figure 111: East Asia Market Value Share, by Country (2022 E)
Figure 112: East Asia Market Attractiveness Analysis by Test, 2022 to 2032
Figure 113: East Asia Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 114: East Asia Market Attractiveness Analysis by End User, 2022 to 2032
Figure 115: East Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 116: China Market Value Proportion Analysis, 2021
Figure 117: Global Vs. China Growth Comparison, 2021 to 2032
Figure 118: China Market Share Analysis (%) by Test, 2021 to 2032
Figure 119: China Market Share Analysis (%) by Infection, 2021 to 2032
Figure 120: China Market Share Analysis (%) by End User, 2021 to 2032
Figure 121: Japan Market Value Proportion Analysis, 2021
Figure 122: Global Vs. Japan Growth Comparison, 2021 to 2032
Figure 123: Japan Market Share Analysis (%) by Test, 2021 to 2032
Figure 124: Japan Market Share Analysis (%) by Infection, 2021 to 2032
Figure 125: Japan Market Share Analysis (%) by End User, 2021 to 2032
Figure 126: South Korea Market Value Proportion Analysis, 2021
Figure 127: Global Vs South Korea Growth Comparison, 2021 to 2032
Figure 128: South Korea Market Share Analysis (%) by Test, 2021 to 2032
Figure 129: South Korea Market Share Analysis (%) by Infection, 2021 to 2032
Figure 130: South Korea Market Share Analysis (%) by End User, 2021 to 2032
Figure 131: South Asia Market Value (US$ Million) Analysis, 2012 to 2021
Figure 132: South Asia Market Value (US$ Million) Forecast, 2022 to 2032
Figure 133: South Asia Market Value Share, by Test (2022 E)
Figure 134: South Asia Market Value Share, by Infection (2022 E)
Figure 135: South Asia Market Value Share, by End User (2022 E)
Figure 136: South Asia Market Value Share, by Country (2022 E)
Figure 137: South Asia Market Attractiveness Analysis by Test, 2022 to 2032
Figure 138: South Asia Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 139: South Asia Market Attractiveness Analysis by End User, 2022 to 2032
Figure 140: South Asia Market Attractiveness Analysis by Country, 2022 to 2032
Figure 141: India Market Value Proportion Analysis, 2021
Figure 142: Global Vs. India Growth Comparison, 2021 to 2032
Figure 143: India Market Share Analysis (%) by Test, 2021 to 2032
Figure 144: India Market Share Analysis (%) by Infection, 2021 to 2032
Figure 145: India Market Share Analysis (%) by End User, 2021 to 2032
Figure 146: Indonesia Market Value Proportion Analysis, 2021
Figure 147: Global Vs. Indonesia Growth Comparison, 2021 to 2032
Figure 148: Indonesia Market Share Analysis (%) by Test, 2021 to 2032
Figure 149: Indonesia Market Share Analysis (%) by Infection, 2021 to 2032
Figure 150: Indonesia Market Share Analysis (%) by End User, 2021 to 2032
Figure 151: Malaysia Market Value Proportion Analysis, 2021
Figure 152: Global Vs. Malaysia Growth Comparison, 2021 to 2032
Figure 153: Malaysia Market Share Analysis (%) by Test, 2021 to 2032
Figure 154: Malaysia Market Share Analysis (%) by Infection, 2021 to 2032
Figure 155: Malaysia Market Share Analysis (%) by End User, 2021 to 2032
Figure 156: Thailand Market Value Proportion Analysis, 2021
Figure 157: Global Vs. Thailand Growth Comparison, 2021 to 2032
Figure 158: Thailand Market Share Analysis (%) by Test, 2021 to 2032
Figure 159: Thailand Market Share Analysis (%) by Infection, 2021 to 2032
Figure 160: Thailand Market Share Analysis (%) by End User, 2021 to 2032
Figure 161: Oceania Market Value (US$ Million) Analysis, 2012 to 2021
Figure 162: Oceania Market Value (US$ Million) Forecast, 2022 to 2032
Figure 163: Oceania Market Value Share, by Test (2022 E)
Figure 164: Oceania Market Value Share, by Infection (2022 E)
Figure 165: Oceania Market Value Share, by End User (2022 E)
Figure 166: Oceania Market Value Share, by Country (2022 E)
Figure 167: Oceania Market Attractiveness Analysis by Test, 2022 to 2032
Figure 168: Oceania Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 169: Oceania Market Attractiveness Analysis by End User, 2022 to 2032
Figure 170: Oceania Market Attractiveness Analysis by Country, 2022 to 2032
Figure 171: Australia Market Value Proportion Analysis, 2021
Figure 172: Global Vs. Australia Growth Comparison, 2021 to 2032
Figure 173: Australia Market Share Analysis (%) by Test, 2021 to 2032
Figure 174: Australia Market Share Analysis (%) by Infection, 2021 to 2032
Figure 175: Australia Market Share Analysis (%) by End User, 2021 to 2032
Figure 176: New Zealand Market Value Proportion Analysis, 2021
Figure 177: Global Vs New Zealand Growth Comparison, 2021 to 2032
Figure 178: New Zealand Market Share Analysis (%) by Test, 2021 to 2032
Figure 179: New Zealand Market Share Analysis (%) by Infection, 2021 to 2032
Figure 180: New Zealand Market Share Analysis (%) by End User, 2021 to 2032
Figure 181: Middle East & Africa Market Value (US$ Million) Analysis, 2012 to 2021
Figure 182: Middle East & Africa Market Value (US$ Million) Forecast, 2022 to 2032
Figure 183: Middle East & Africa Market Value Share, by Test (2022 E)
Figure 184: Middle East & Africa Market Value Share, by Infection (2022 E)
Figure 185: Middle East & Africa Market Value Share, by End User (2022 E)
Figure 186: Middle East & Africa Market Value Share, by Country (2022 E)
Figure 187: Middle East & Africa Market Attractiveness Analysis by Test, 2022 to 2032
Figure 188: Middle East & Africa Market Attractiveness Analysis by Infection, 2022 to 2032
Figure 189: Middle East & Africa Market Attractiveness Analysis by End User, 2022 to 2032
Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032
Figure 191: GCC Countries Market Value Proportion Analysis, 2021
Figure 192: Global Vs GCC Countries Growth Comparison, 2021 to 2032
Figure 193: GCC Countries Market Share Analysis (%) by Test, 2021 to 2032
Figure 194: GCC Countries Market Share Analysis (%) by Infection, 2021 to 2032
Figure 195: GCC Countries Market Share Analysis (%) by End User, 2021 to 2032
Figure 196: Turkey Market Value Proportion Analysis, 2021
Figure 197: Global Vs. Turkey Growth Comparison, 2021 to 2032
Figure 198: Turkey Market Share Analysis (%) by Test, 2021 to 2032
Figure 199: Turkey Market Share Analysis (%) by Infection, 2021 to 2032
Figure 200: Turkey Market Share Analysis (%) by End User, 2021 to 2032
Figure 201: South Africa Market Value Proportion Analysis, 2021
Figure 202: Global Vs. South Africa Growth Comparison, 2021 to 2032
Figure 203: South Africa Market Share Analysis (%) by Test, 2021 to 2032
Figure 204: South Africa Market Share Analysis (%) by Infection, 2021 to 2032
Figure 205: South Africa Market Share Analysis (%) by End User, 2021 to 2032
Figure 206: North Africa Market Value Proportion Analysis, 2021
Figure 207: Global Vs North Africa Growth Comparison, 2021 to 2032
Figure 208: North Africa Market Share Analysis (%) by Test, 2021 to 2032
Figure 209: North Africa Market Share Analysis (%) by Infection, 2021 to 2032
Figure 210: North Africa Market Share Analysis (%) by End User, 2021 to 2032
The global anti-microbial/anti-fungal tests market is worth USD 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.
The anti-microbial/anti-fungal tests market is expected to reach USD 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.
The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.
USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.
North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.
Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.
Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.
China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.
Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.
Anti-microbial/Anti-fungal Tests Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
